Short Interest in Oncolytics Biotech, Inc. (NASDAQ:ONCY) Rises By 245.6%
Oncolytics Biotech, Inc. (NASDAQ:ONCY) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 599,600 shares, a growth of 245.6% from the July 31st total of 173,500 shares. Currently, 3.0% of the shares of the company are short sold. Based on an average trading volume of 153,100 shares, the short-interest ratio is presently 3.9 days.
NASDAQ:ONCY remained flat at $$0.71 during trading hours on Wednesday. The company had a trading volume of 131,674 shares, compared to its average volume of 120,771. The firm has a market capitalization of $17.73 million, a P/E ratio of -0.87 and a beta of 2.23. Oncolytics Biotech has a 1-year low of $0.53 and a 1-year high of $5.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.21 and a quick ratio of 3.21. The firm has a fifty day moving average of $0.88 and a 200 day moving average of $1.58.
Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.19) EPS for the quarter. On average, equities research analysts forecast that Oncolytics Biotech will post -0.92 EPS for the current year.
An institutional investor recently bought a new position in Oncolytics Biotech stock. Verition Fund Management LLC bought a new position in shares of Oncolytics Biotech, Inc. (NASDAQ:ONCY) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 408,838 shares of the company’s stock, valued at approximately $695,000. Verition Fund Management LLC owned approximately 2.01% of Oncolytics Biotech as of its most recent filing with the SEC. Institutional investors own 2.32% of the company’s stock.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Featured Article: Retained Earnings
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.